IL-28B rs12979860 polymorphism affect the course of chronic hepatitis and the development of HCC in Egyptian patients with hepatitis C type 4. Issue 4 (2nd October 2018)

• Record Type: Journal Article
• Authors: Attallah, AM; Omran, D; Marie, M S; Abdelrazek, Mohamed; Salama, A; El Essawey, R; Mobarak, L; Maklad, S; Omar, A
• Is Part Of: British journal of biomedical science. Volume 75:Issue 4(2018)
• Page Start: 157
• Page End: 162
• Publication Date: 2018-10-02
• Subjects: IL-28B -- genotypes -- polymorphisms -- chronic hepatitis C -- hepatocellular carcinoma -- rs12979860; Medical sciences -- Periodicals; Medical technology -- Periodicals; Biological Science Disciplines; Clinical Laboratory Techniques; Medical Laboratory Science; Anatomie pathologique; Medical sciences; Medical technology; Klinische chemie; Laboratoriumonderzoek; Periodicals; Periodicals; 616.0756; 610.07 M489L
• DOI: 10.1080/09674845.2018.1489599
• Languages: English
• ISSNs: 0967-4845

Abstract

ABSTRACT: Background : A single nucleotide polymorphism (SNP) in the interleukin 28B (IL28B) gene may alter the trajectory of hepatitis C virus (HCV) chronic infection. Several studies have sought to determine a link between IL28B rs12979860 SNP and the development of HCV-related hepatocellular carcinoma (HCC), but with variable results, and consensus is awaited. We hypothesised that IL28B rs12979860 SNP is linked to HCC in patients with HCV type 4. Methods : IL28B genotyping of 300 patients with HCV-related fibrosis (n = 100), cirrhosis (n = 100) and HCC (n = 100) was carried out and the results were analysed to determine the association between the IL28B genotype and clinical outcome. Results : In IL28B TT genotype carriers, the proportions of moderate/severe fibrosis, advanced cirrhosis (Child B-C) and HCC (50%, 84% and 60.2%, respectively) were higher ( p < 0.05) than in CC/CT (4.3%, 46% and 23%, respectively). IL-28B SNP was linked significantly ( p < 0.05) with cirrhosis progression and HCC advanced stages. Moreover, HCC advanced Child, Okuda and CLIP stages were associated with T allele carriage (73.9%, 82.6% and 78.3% vs . 44.2%, 50.6% and 46.8% in CC/CT). The percentage of large tumour size (> 3cm) increased ( p = 0.028) in TT genotype carriers (81.8% vs .52.6% in CC/CT). Conclusion : IL-28B rs12979860 TT genotype is more prevalent in patients with advanced fibrosis, cirrhosis and HCC stages. Thus, it seems to be associated with poor outcomes in chronic HCV patients and to augment the risk of developing HCC.